Submitted by Catherine Atkins on Mon, 02/03/2026 - 16:38
A new review by clinicians and scientists from the Cambridge Stem Cell Institute and the Early Cancer Institute, University of Cambridge, highlights how advances in cancer genomics are reshaping early detection and prevention of different cancers.
Drawing on two decades of cancer genomics research, the article explains how scientists can now identify cancer-related genetic and epigenetic changes long before symptoms appear. Central to these efforts are minimally invasive tests that detect tumour-derived DNA fragments in blood and other body fluids, offering the potential to screen for multiple cancer types from a single sample. The review also addresses a critical biological insight: many healthy tissues accumulate small populations of cells carrying cancer-associated mutations with age, yet only a minority progress to malignancy. By analysing features such as mutation type, clone size, and growth dynamics, researchers are developing models that identify individuals at highest risk. Together, these advances point towards a future of precision screening, earlier intervention, targeted prevention strategies, and improving outcomes through detection of premalignant/precursor states.
The review article was published in Nature Genetics (Ref: Gu et al, Nat Genet DOI:10.1038/s41588-026-02505-1)